Lactobacillus delbrueckii CIDCA 133 Ameliorates Chemotherapy-Induced Mucositis by Modulating Epithelial Barrier and TLR2/4/Myd88/NF-κB Signaling Pathway

Lactobacillus delbrueckii CIDCA 133 Ameliorates Chemotherapy-Induced Mucositis by Modulating Epithelial Barrier and TLR2/4/Myd88/NF-κB Signaling Pathway

Intestinal mucositis promoted by the use of anticancer drugs is characterized by ulcerative inflammation of the intestinal mucosa, a debilitating side effect in cancer patients undergoing treatment. Probiotics are a potential therapeutic option to alleviate intestinal mucositis due to their effects...

Full description

Bibliographic Details
Main Authors: Fernanda Alvarenga Lima Barroso, Luís Cláudio Lima de Jesus, Tales Fernando da Silva, Viviane Lima Batista, Juliana Laguna, Nina Dias Coelho-Rocha, Kátia Duarte Vital, Simone Odília Antunes Fernandes, Valbert Nascimento Cardoso, Enio Ferreira, Flaviano Santos Martins, Mariana Martins Drumond, Pamela Mancha-Agresti, Alexander Birbrair, Debmalya Barh, Vasco Azevedo
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Microbiology
Subjects:
5-FU-induced mucositis
probiotics
Lactobacillus delbrueckii
anti-inflammatory cytokines
intestinal permeability
tight junction proteins
Online Access:https://www.frontiersin.org/articles/10.3389/fmicb.2022.858036/full

Internet

https://www.frontiersin.org/articles/10.3389/fmicb.2022.858036/full

Similar Items